Febuxostat is assoc w/ a reduced risk of kidney events and slower decline in eGFR. Metanalysis of 16 RCTs, shows febuxostat w/a reduced risk of kidney events (RR=0.56) & slower decline in eGFR; & reduced urine albumin to creatinine ratio https://t.co/GQ8UopbA88 https://t.co/WQskc1yZ02